Circulating Biomarker Market Driven by Increasing Accuracy of Cancer Diagnosis due to Circulating Biomarker Analysis

Circulating Biomarker Market
Circulating Biomarker Market announces the addition of a new report to its growing market intelligence repository. The report analyzes the global circulating biomarker market in detail and provides a clear look at the market’s likely trajectory in the 2017-2022 forecast period. The report uses detailed 2012-2017 figures in order to establish a firm platform for market projections, providing a comprehensive view into the development of the circulating biomarker market. The report is titled ‘Global Circulating Biomarker Detailed Analysis Report 2017-2022.’

It covers various growth drivers and restraints leaving a strong impact on the overall market. Opportunities promising to bolster the market’s growth are highlighted as well. The report therefore contains exhaustive information crucial for market players looking to establish a stronghold in the global circulating biomarker market. It also segments the market based on various parameters to identify various factors enabling growth across these segments.

Circulating biomarkers have become important in cancer research due to the aid they provide in pinpointing the morphological makeup of the cancer in question. Conventional diagnosis methods for cancer relied on samples taken from individual biopsy sites, which could provide misleading results due to the high probability of heterogeneity between multiple tumors. Metastatic cancers, which present the worst prognoses, can thus be better controlled by analyzing circulating biomarkers, which provide a more accurate look into the makeup of the disease in individual patients. Circulating biomarkers include genetic material, which remains largely consistent regardless of the site of the tumor. The steady advancement of nucleic acid analysis methods has allowed researchers to assess genetic biomarkers in greater detail, which is likely to drive development of the circulating biomarkers sector in the coming years.

For Sample Copy, click here:

The report segments the circulating biomarker market by cancer type into colorectal cancer, breast cancer, lung cancer, and prostate cancer. By biomarker type, the circulating biomarker market is segmented into circulating tumor cells and circulating tumor DNA. Of these, circulating tumor DNA is likely to dominate the circulating biomarker sector in the coming years due to the greater accuracy it provides in cancer diagnosis. By application, the circulating biomarker market is likely to be dominated by research laboratories in the coming years, followed by reference laboratories. The report provides 2012-2017 historical figures for each sector of the circulating biomarker market and further 2017-2022 projections.

Geographically, the global circulating biomarker market is segmented into North America, Latin America, Europe, Asia Pacific, Southeast Asia, and the Middle East and Africa. Key national markets covered in the report include the U.S., Canada, Brazil, Mexico, Argentina, Germany, the U.K., France, Italy, Spain, Russia, the Netherlands, China, Japan, India, South Korea, Australia, Indonesia, Vietnam, the Philippines, Thailand, Malaysia, Singapore, Egypt, South Africa, Turkey, Saudi Arabia, and Iran. The report provides detailed 2012-2022 trajectories of each national market in order to elaborate upon the development prospects of the circulating biomarker market in each key region.

Developed countries such as the U.S., Germany, and the U.K. are home to advanced cancer research laboratories and are thus likely to dominate proceedings in the circulating biomarker market in the coming years. Rising Asia Pacific and Southeast Asian economies are also home to booming medical research and pharmaceutical sectors and are thus likely to remain influential in the global circulating biomarker market.

The report also assesses the leading companies in the global circulating biomarker market in order to examine the competitive dynamics of the market. Key companies examined in the report include Biocept Inc., QIAGEN, Trovagene, Guardant Health, MDxHealth SA, Bio-Rad Laboratories, Roche, Janssen Diagnostics, Myriad Genetics, and Fraunhofer-Gesselschaft.

Leave a Reply